Integra Lifesciences Holdings CORP 10-Q quarterly reports

Integra LifeSciences Holdings Corporation announced its financial results for the second quarter ended June 30, 2026, reporting a net income of $4.5 million.

Integra LifeSciences Holdings Corporation announced its first quarter 2026 financial results, reporting a reduced net loss compared to the prior year, driven by improved operational performance and revenue growth.

Integra LifeSciences reported a significant net loss for the nine months ended September 30, 2025, primarily due to a $511.4 million goodwill impairment charge and ongoing operational challenges, despite a slight increase in total revenue.

Integra LifeSciences Holdings Corporation reported a substantial net loss for the second quarter and first half of 2025, primarily driven by a $511.4 million goodwill impairment charge, alongside declining gross margins and negative operating cash flow.

Integra LifeSciences' Q1 2025 results reveal a net loss, influenced by quality and operational challenges, despite revenue increase driven by the Acclarent acquisition.

Integra LifeSciences experienced a net loss in Q3 2024, impacted by acquisition costs and operational issues, despite a slight revenue decrease.

Integra LifeSciences' second quarter results show a net loss, impacted by acquisition costs and manufacturing issues, despite revenue growth driven by the Acclarent acquisition.

Integra LifeSciences' first quarter results for 2024 show a net loss, primarily due to manufacturing challenges and impairment charges, contrasting with a net income in the same period last year.